Fate therapeutics reports new employee inducement awards under nasdaq listing rule 5635(c)(4)

San diego, feb. 04, 2025 (globe newswire) -- fate therapeutics, inc. (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (ipsc)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on february 3, 2025 the company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 35,000 shares of the company's common stock at an exercise price per share of $1.27, which was the closing price per share of the company's common stock as reported by nasdaq on february 3, 2025, the options grant date, and (ii) restricted stock units (rsus) representing 20,400 shares of its common stock to two newly-hired non-executive employees. the grants were approved by the compensation committee of the company's board of directors and granted under the company's amended and restated inducement equity plan as an inducement material to the new employees entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4). the options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the company through each vesting date. the rsus will vest over four years, with 25% of the shares underlying each rsu award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the company through each vesting date.
NDAQ Ratings Summary
NDAQ Quant Ranking